Your browser is no longer supported. Please, upgrade your browser.
Settings
VRTX Vertex Pharmaceuticals Incorporated daily Stock Chart
VRTX [NASD]
Vertex Pharmaceuticals Incorporated
IndexS&P 500 P/E23.30 EPS (ttm)8.07 Insider Own0.20% Shs Outstand254.88M Perf Week3.71%
Market Cap47.94B Forward P/E29.10 EPS next Y6.46 Insider Trans-41.09% Shs Float254.47M Perf Month1.03%
Income2.10B PEG0.43 EPS next Q1.02 Inst Own98.90% Short Float1.42% Perf Quarter10.43%
Sales3.05B P/S15.73 EPS this Y678.20% Inst Trans1.75% Short Ratio2.37 Perf Half Y8.71%
Book/sh17.40 P/B10.81 EPS next Y49.23% ROA43.80% Target Price207.53 Perf Year19.59%
Cash/sh12.43 P/C15.13 EPS next 5Y53.86% ROE67.50% 52W Range144.07 - 195.81 Perf YTD13.49%
Dividend- P/FCF40.80 EPS past 5Y41.20% ROI42.20% 52W High-3.95% Beta1.68
Dividend %- Quick Ratio3.30 Sales past 5Y20.30% Gross Margin86.60% 52W Low30.54% ATR4.27
Employees2500 Current Ratio3.40 Sales Q/Q33.50% Oper. Margin20.80% RSI (14)57.54 Volatility1.62% 2.33%
OptionableYes Debt/Eq0.13 EPS Q/Q1440.00% Profit Margin68.80% Rel Volume0.92 Prev Close185.72
ShortableYes LT Debt/Eq0.13 EarningsFeb 05 AMC Payout0.00% Avg Volume1.53M Price188.07
Recom1.90 SMA200.45% SMA505.64% SMA2009.23% Volume1,408,239 Change1.27%
Feb-06-19Downgrade Maxim Group Buy → Hold
Jan-02-19Downgrade Raymond James Outperform → Mkt Perform
Oct-26-18Upgrade H.C. Wainwright Neutral → Buy $220
Oct-01-18Initiated Cantor Fitzgerald Overweight $217
Aug-07-18Reiterated Stifel Buy $182 → $200
Mar-05-18Reiterated Maxim Group Buy $195 → $200
Feb-13-18Reiterated JMP Securities Mkt Outperform $200 → $211
Feb-01-18Reiterated Barclays Overweight $180 → $200
Jan-05-18Upgrade BofA/Merrill Neutral → Buy
Oct-18-17Reiterated RBC Capital Mkts Outperform $175 → $181
Sep-29-17Initiated BTIG Research Buy $200
Sep-15-17Initiated RBC Capital Mkts Outperform $175
Jul-19-17Upgrade Raymond James Mkt Perform → Outperform
Jul-19-17Upgrade Janney Neutral → Buy
Jul-19-17Upgrade Barclays Equal Weight → Overweight $115 → $180
Jul-19-17Reiterated Stifel Buy $154 → $182
Jul-18-17Reiterated Stifel Buy $130 → $154
Jul-11-17Initiated Jefferies Buy
Jun-23-17Upgrade Needham Hold → Buy $155
Jun-02-17Upgrade Oppenheimer Perform → Outperform
Feb-17-19 09:12AM  3 Most Profitable Drugmakers in the S&P 500 -- Are They Buys? Motley Fool
Feb-14-19 09:04AM  Positive Phase 3 Study for Tezacaftor/Ivacaftor Combination in Children Aged 6-11 Years with Cystic Fibrosis Supports European Medicines Agency Submission Business Wire
Feb-13-19 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $20.1 million of Shares GuruFocus.com
11:26AM  Have Insiders Been Selling Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Shares? Simply Wall St.
Feb-11-19 08:05AM  Groupon (GRPN) to Report Q4 Earnings: What's in the Cards? Zacks
Feb-10-19 09:00AM  This Is the Best Biotech Stock on the Market Motley Fool
Feb-08-19 10:53AM  Check Out These 7 Fast-Growing Stocks to Buy Today InvestorPlace
07:04AM  Factors Likely to Influence Cisco's (CSCO) Earnings in Q2 Zacks
05:07AM  Factors Expected to Influence Akamai's (AKAM) Q4 Earnings Zacks
Feb-07-19 03:33PM  Vertex Pharmaceuticals: New Drug, Same Great Growth Story Motley Fool
09:39AM  The Zacks Analyst Blog Highlights: Gilead, Vertex, Celgene, Alkermes and AVEO Zacks
Feb-06-19 06:15PM  Vertex Pharmaceuticals Inc (VRTX) CEO & President Jeffrey M Leiden Sold $6 million of Shares GuruFocus.com
10:31AM  Vertex (VRTX) Q4 Earnings Beat on Solid CF Products Sales Zacks
10:12AM  Stocks Turn Lower, But These Top Stocks Break Out On Earnings Investor's Business Daily
08:23AM  The Daily Biotech Pulse: Paratek Launches Antibiotic In US, Eli Lilly Earnings, Catabasis Offering Benzinga
08:10AM  Vertex Pharmaceuticals (VRTX) Q4 2018 Earnings Conference Call Transcript Motley Fool
07:28AM  Dow Jones Futures: Snap Soars, But These 4 Top Stocks Are Crossing Buy Points Investor's Business Daily
07:06AM  Biotech Stock Roundup: Celgene Tops in Q4, Gilead Disappoints, ALKS & AVEO Sink Zacks
Feb-05-19 05:20PM  Vertex Pharmaceuticals (VRTX) Q4 Earnings and Revenues Top Estimates Zacks
05:09PM  This Key Biotech Franchise Tacked On 40% Growth In Fourth-Quarter Sales Investor's Business Daily
04:19PM  Vertex: 4Q Earnings Snapshot Associated Press
04:01PM  Vertex Reports Full-Year and Fourth-Quarter 2018 Financial Results Business Wire
02:30PM  Vertex Pharmaceuticals Incorporated to Host Earnings Call ACCESSWIRE
11:06AM  Vertex Earnings, Revenue beat in Q4 Investing.com
Feb-04-19 08:58AM  Regeneron (REGN) to Report Q4 Earnings: Is a Beat in Store? Zacks
08:55AM  Qorvo (QRVO) to Report Q3 Earnings: What's in the Cards? Zacks
Feb-01-19 09:48AM  6 Biotech Stocks to Watch Now Motley Fool
Jan-31-19 07:18PM  Will Gilead (GILD) Q4 Earnings Disappoint on Weak HCV Sales? Zacks
07:35AM  Report: Exploring Fundamental Drivers Behind TD Ameritrade Holding, Vertex Pharmaceuticals, Arrowhead Pharmaceuticals, Nucor, Portland General Electric, and TrueBlue New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Jan-30-19 10:02AM  Is a Beat in Store for Vertex (VRTX) This Earnings Season? Zacks
Jan-29-19 09:30PM  3 Top Biotech Stocks to Buy Right Now Motley Fool
10:31AM  Vertex Pharmaceuticals (VRTX) Earnings Expected to Grow: Should You Buy? Zacks
10:11AM  Vertex's Kalydeco Wins Health Canada Nod to Treat CF in Kids Zacks
10:00AM  Is a Beat in the Cards for Celgene (CELG) in Q4 Earnings? Zacks
Jan-28-19 09:17AM  Health Canada Grants Market Authorization for KALYDECO® (ivacaftor) in Children Ages 12 to <24 months with Certain Mutations in the CFTR Gene Business Wire
Jan-26-19 06:10PM  Is Vertex Pharmaceuticals a Buy? Motley Fool
Jan-25-19 10:20AM  Hot Stocks Boost USAA Aggressive Growth Investor's Business Daily
09:44AM  Merck KGaA Gives Vertex Rights to Two Gene-Editing Compounds Zacks
Jan-24-19 10:46AM  Vertex Terminates COO Ian Smith on Code of Conduct Violation Zacks
08:00AM  Merck KGaA, Darmstadt, Germany, Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors PR Newswire
08:00AM  Merck Grants Exclusive License to Vertex for Two DNA Damage Response Inhibitors CNW Group
07:59AM  Stocks making the biggest moves premarket: Southwest, Apple, Ford Motor & more CNBC
Jan-23-19 06:39PM  [$$] Vertex Pharmaceuticals Fires Executive for Conduct Violation The Wall Street Journal
05:51PM  Vertex Pharmaceuticals fires executive for 'personal behavior' American City Business Journals
05:13PM  Vertex Pharma boots out COO for "personal behavior" violations Reuters
04:41PM  Vertex Pharma terminates interim CFO's employment for code violations Reuters
04:30PM  Vertex terminates COO for 'personal behavior' MarketWatch
04:05PM  Vertex Announces Departure of Ian Smith, Names Interim CFO Business Wire
10:31AM  Vertex Pharmaceuticals (VRTX) Reports Next Week: Wall Street Expects Earnings Growth Zacks
09:30AM  CELG or VRTX: Which Is the Better Value Stock Right Now? Zacks
09:12AM  Biotech Stock Roundup: Amgen, Vertex Get EC Nod for Label Expansion of Drugs Zacks
08:18AM  Better Buy: CRISPR Therapeutics vs. Editas Medicine Motley Fool
Jan-22-19 04:01PM  Vertex to Announce Full-Year and Fourth-Quarter 2018 Financial Results on February 5 Business Wire
09:31AM  Vertex's Orkambi Wins EU Nod to Treat Cystic Fibrosis in Kids Zacks
Jan-21-19 10:10AM  Why Vertex (VRTX) is Poised to Beat Earnings Estimates Again Zacks
04:00AM  Vertex Announces European Commission Approval for ORKAMBI® (lumacaftor/ivacaftor) for Treatment of Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease Business Wire
Jan-12-19 12:00PM  Where Will CRISPR Therapeutics Be in 10 Years? Motley Fool
07:31AM  3 Biotech Stocks to Watch in 2019 Motley Fool
Jan-11-19 04:18PM  Stocks Pare Losses As Small Caps Lead; Why Netflix Led The IBD 50 Investor's Business Daily
04:14PM  Why This IBD Stock Of The Day Broke Out Despite Biotech Turbulence Investor's Business Daily
12:08PM  Vertex Pharmaceuticals Begins Forming A Base Investor's Business Daily Video
Jan-09-19 10:04AM  Moderna (MRNA) Announces Pipeline Progress, Shares Rise Zacks
Jan-08-19 10:12AM  Is Vertex Pharmaceuticals Incorporateds (NASDAQ:VRTX) CEO Being Overpaid? Simply Wall St.
07:15AM  5 Things to Expect for Vertex Pharmaceuticals in 2019 Motley Fool
Jan-07-19 10:03AM  Vertex, CRISPR's Sickle Disease Drug Gets FDA's Fast Track Tag Zacks
Jan-06-19 09:32AM  Outlook For Battered Biotech Stocks In 2019 Investopedia
09:09AM  Better Buy: CRISPR Therapeutics vs. Vertex Pharmaceuticals Motley Fool
Jan-04-19 04:24PM  These Stocks Pop After FDA Expedites Review Of Gene-Editing Therapy Investor's Business Daily +5.48%
10:01AM  Vertex Joins Forces With Arbor to Build Gene-Editing Therapies Zacks
07:00AM  CRISPR Therapeutics and Vertex Announce FDA Fast Track Designation for CTX001 for the Treatment of Sickle Cell Disease GlobeNewswire
Jan-03-19 10:33AM  Vertex teams up with Feng Zhang startup on gene editing tech American City Business Journals
08:00AM  Vertex and Arbor Biotechnologies Establish Collaboration to Discover Novel Proteins to Advance Discovery of Gene-Editing Therapies Business Wire
Jan-02-19 04:27PM  Could This New Biotech IPO Could Score Big With A Cancer Vaccine? Investor's Business Daily
04:01PM  Vertex to Present at the J.P. Morgan Healthcare Conference on January 7 Business Wire
Dec-26-18 02:22PM  6 Valuable Pipeline Drugs With Upcoming Catalysts Benzinga +6.54%
11:50AM  HC Wainwright Bullish On Corbus Therapeutics' Cystic Fibrosis Opportunity Benzinga
Dec-20-18 06:47PM  Stocks - Dow's Dour December Continues Amid Turmoil in Washington Investing.com
12:15PM  5 Low-Priced Stocks Under $10 for the New Year InvestorPlace
10:13AM  The Zacks Analyst Blog Highlights: Amgen, Aduro, Vertex, Evofem and Incyte Zacks
Dec-19-18 12:04PM  Vertex Announces it will Submit Cystic Fibrosis Medicines ORKAMBI® (lumacaftor/ivacaftor) as well as SYMKEVI® (tezacaftor/ivacaftor) to be Used in Combination with ivacaftor, to the Scottish Medicines Consortium for Appraisal Business Wire
09:17AM  Biotech Stock Roundup: Pipeline Updates From VRTX & AMGN, ADRO Teams Up With LLY Zacks
09:12AM  Vertex's (VRTX) 3rd Study on Pain Drug Meets Primary Endpoint Zacks
05:37AM  Waltham's Eloxx aims to reach cystic fibrosis patients that Vertex can't American City Business Journals
Dec-18-18 08:55AM  Biotechs Were Innovators In 2018: Here Are The Top New Molecules That Were Approved Benzinga
08:30AM  Vertex Announces Positive Phase 2 Data in Third Proof-of-Concept Study with the NaV1.8 Inhibitor VX-150 Business Wire
07:17AM  3 Biotechs With Potential Blockbusters Near the Finish Line Motley Fool
Dec-17-18 07:00AM  Report finds growing pains for rare disease drugs, but local biotechs buck trend American City Business Journals
Dec-14-18 08:23AM  5 Drug/Biotech Stocks With Promise to Sustain Bull Run in 2019 Zacks
Dec-13-18 08:00AM  Health Canada Grants Market Authorization for ORKAMBI® (lumacaftor/ivacaftor) for Children with Cystic Fibrosis Aged 2 to 5 Years Old with Most Common Form of the Disease Business Wire
07:32AM  Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)? Zacks
Dec-10-18 08:41AM  Should Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Be Your Next Stock Pick? Simply Wall St.
07:58AM  5 Top Drug/Biotech Merger & Acquisition Targets for 2019 Zacks
Dec-09-18 11:50AM  Should You Avoid Vertex Pharmaceuticals Incorporated (VRTX)? Insider Monkey
Dec-07-18 02:24PM  3 Highest-Growth Stocks in Today's Market Motley Fool
Dec-05-18 09:10AM  Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China Zacks
Dec-03-18 04:18PM  Monday Madness: Ready to Add Some Stocks to Your Holiday Wishlist? TheStreet.com
11:17AM  Top Analysts: Five 'Strong Buy' Stocks for 2019 TheStreet.com
Dec-01-18 12:00PM  Better Buy: Vertex Pharmaceuticals vs. Regeneron Pharmaceuticals Motley Fool
Nov-30-18 10:31AM  Why Crispr Therapeutics Stock Is Up By 65% So Far in 2018 Motley Fool
Nov-29-18 04:05PM  Moderna IPO On Path To Be Largest Offering Of Venture-Backed Biotech Investor's Business Daily
Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company focuses on developing and commercializing therapies for treating cystic fibrosis (CF) and advancing its research and development programs. It markets ORKAMBI (lumacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are homozygous for the F508del mutation in their cystic fibrosis transmembrane conductance regulator (CFTR) gene; KALYDECO (ivacaftor) for treating patients with CF who have specific mutations in their CFTR gene, including the G551D mutation; and SYMDEKO (tezacaftor in combination with ivacaftor) to treat patients with CF 12 years of age and older who are F508del homozygous or who have 1 mutation that is responsive to tezacaftor/ivacaftor. The company also develops VX-659 and VX-445, which are CFTR corrector compounds in Phase II clinical trial; VX-150 that is in Phase II clinical trial to treat pain; VX-128, which is in Phase I clinical trial for treating pain; CTX001, which is in Phase I/II trial for treating beta-thalassemia and sickle cell disease; pimodivir (JNJ-63623872), which is in a Phase III clinical development program to treat influenza; and VX-210 to treat acute spinal cord injury. It sells its products primarily to specialty pharmacy providers in North America, as well as government-owned and supported customers internationally. The company has collaborations with Cystic Fibrosis Foundation Therapeutics Incorporated; CRISPR Therapeutics AG; Moderna Therapeutics, Inc.; BioAxone Biosciences, Inc.; Parion Sciences, Inc.; Merck KGaA; Janssen Pharmaceuticals, Inc; and Q-State Biosciences, Inc., as well as a research collaboration with Arbor Biotechnologies to discover DNA endonucleases for cystic fibrosis and four other diseases. It also has a collaboration with X-Chem, Inc. to develop DNA-encoded DEX libraries. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Silva Paul MSVP & Interim CFOFeb 11Sale180.164,215759,36720,571Feb 13 04:27 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 11Sale180.2133,0735,959,96938,864Feb 13 04:37 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 11Sale180.2232,9565,939,18837,177Feb 13 04:36 PM
Sachdev AmitEVP, CROFeb 11Sale180.0635,0956,319,21640,165Feb 13 04:40 PM
LEIDEN JEFFREY MCEO & PresidentFeb 11Sale180.24111,43120,083,804127,192Feb 13 04:39 PM
Silva Paul MSVP & Interim CFOFeb 06Option Exercise91.051,289117,36313,938Feb 07 04:04 PM
Silva Paul MSVP & Interim CFOFeb 06Sale193.001,289248,77712,649Feb 07 04:04 PM
Parini MichaelEVP, CL&AOFeb 04Option Exercise86.522,330201,59238,489Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Option Exercise88.494,126365,11741,443Feb 06 04:46 PM
Silva Paul MSVP & Interim CFOFeb 04Option Exercise86.5280969,99516,896Feb 06 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Option Exercise99.977,959795,65754,711Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Option Exercise88.904,097364,23548,817Feb 06 04:51 PM
Parini MichaelEVP, CL&AOFeb 04Sale189.192,330440,81336,159Feb 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSOFeb 04Sale189.194,126780,59839,113Feb 06 04:46 PM
LEIDEN JEFFREY MCEO & PresidentFeb 04Sale186.3532,2506,009,682124,865Feb 06 04:47 PM
Silva Paul MSVP & Interim CFOFeb 04Sale187.024,247794,27312,649Feb 06 04:49 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerFeb 04Sale186.2018,3093,409,08236,402Feb 06 04:50 PM
Sachdev AmitEVP, CROFeb 04Sale186.8612,7222,377,29638,037Feb 06 04:51 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Option Exercise131.892,125280,26641,238Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Option Exercise131.892,125280,26648,877Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Option Exercise155.573,668570,63143,277Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 22Sale193.482,125411,14539,113Jan 24 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJan 22Sale193.482,125411,14546,752Jan 24 04:46 PM
Parini MichaelEVP, CL&AOJan 22Sale195.003,668715,26039,609Jan 24 04:47 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Option Exercise155.701,223190,42140,336Jan 22 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOJan 18Sale194.621,223238,02039,113Jan 22 04:07 PM
Silva Paul MSVP & Corp ControllerJan 17Option Exercise90.623,007272,48217,376Jan 18 04:18 PM
Silva Paul MSVP & Corp ControllerJan 17Sale190.623,007573,18216,087Jan 18 04:18 PM
Parini MichaelEVP, CL&AOJan 14Option Exercise90.292,125191,86641,734Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 14Sale186.712,125396,75939,609Jan 15 04:03 PM
Parini MichaelEVP, CL&AOJan 04Option Exercise122.454,250520,41343,859Jan 07 04:02 PM
Parini MichaelEVP, CL&AOJan 04Sale165.904,250705,07539,609Jan 07 04:02 PM
SACHS BRUCE IDirectorDec 06Option Exercise34.2410,000342,40023,011Dec 07 04:06 PM
Silva Paul MSVP & Corp ControllerDec 03Option Exercise86.5280969,99516,896Dec 04 04:04 PM
Silva Paul MSVP & Corp ControllerDec 03Sale186.52809150,89516,087Dec 04 04:04 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 15Sale163.7510016,37539,113Nov 19 05:23 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 15Sale163.75294,74946,752Nov 19 05:28 PM
Sachdev AmitEVP, CRONov 15Sale163.75619,98946,662Nov 19 05:34 PM
Parini MichaelEVP, CL&AONov 15Sale163.759014,73839,609Nov 19 05:47 PM
Silva Paul MSVP & Corp ControllerNov 15Sale163.75121,96516,087Nov 19 05:52 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Option Exercise131.892,125280,26641,238Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Option Exercise131.892,125280,26648,877Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 07Sale181.892,125386,51639,113Nov 08 04:18 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 07Sale179.002,125380,37546,752Nov 08 04:26 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Option Exercise86.522,330201,59241,443Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Option Exercise103.095,803598,21151,002Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Option Exercise86.522,330201,59241,939Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Option Exercise86.521,941167,93548,603Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 05Sale172.082,330400,94639,113Nov 06 04:11 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 05Sale172.085,803998,58046,752Nov 06 04:24 PM
Parini MichaelEVP, CL&AONov 05Sale172.082,330400,94639,609Nov 06 04:32 PM
Sachdev AmitEVP, CRONov 05Sale173.731,941337,20446,662Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Option Exercise91.051,796163,52640,909Nov 06 04:11 PM
Sachdev AmitEVP, CRONov 02Option Exercise91.052,155196,21348,817Nov 06 04:45 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Option Exercise91.052,155196,21348,907Nov 05 04:52 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerNov 02Sale175.362,155377,90146,752Nov 05 04:52 PM
Sachdev AmitEVP, CRONov 02Sale172.862,155372,50546,662Nov 06 04:45 PM
ALTSHULER DAVIDEVP, Global Research and CSONov 02Sale175.361,796314,94739,113Nov 06 04:11 PM
Parini MichaelEVP, CL&AOOct 12Option Exercise90.292,125191,86641,734Oct 16 04:29 PM
Parini MichaelEVP, CL&AOOct 12Sale177.202,125376,55039,609Oct 16 04:29 PM
Kewalramani ReshmaEVP and CMOOct 08Sale186.952,305430,9201,909Oct 09 04:50 PM
Parini MichaelEVP, CL&AOOct 04Option Exercise122.454,250520,41343,859Oct 05 05:35 PM
Parini MichaelEVP, CL&AOOct 04Sale191.584,250814,21539,609Oct 05 05:35 PM
Bhatia Sangeeta N.DirectorOct 03Option Exercise126.386,818861,6509,579Oct 05 05:28 PM
Bhatia Sangeeta N.DirectorOct 03Sale192.136,8181,309,9424,879Oct 05 05:28 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Option Exercise155.572,445380,36941,558Oct 02 04:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOOct 01Sale194.622,445475,84639,113Oct 02 04:30 PM
Graney ThomasChief Financial OfficerOct 01Sale193.241,076207,92612,430Oct 02 04:24 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Option Exercise131.892,125280,26641,238Aug 30 04:07 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 28Sale181.892,125386,51639,113Aug 30 04:07 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Option Exercise103.095,803598,21152,555Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 03Option Exercise86.5280969,99516,896Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Option Exercise86.522,330201,59241,443Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 03Option Exercise86.521,942168,02248,604Aug 06 06:19 PM
Parini MichaelEVP, CL&AOAug 03Option Exercise86.522,330201,59241,939Aug 07 04:46 PM
Parini MichaelEVP, CL&AOAug 03Sale174.202,330405,88639,609Aug 07 04:46 PM
Sachdev AmitEVP, CROAug 03Sale175.101,942340,05046,662Aug 06 06:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 03Sale174.202,330405,88639,113Aug 06 05:42 PM
Silva Paul MSVP & Corp ControllerAug 03Sale174.20809140,92816,087Aug 06 05:38 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 03Sale174.205,8031,010,88346,752Aug 06 05:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Option Exercise111.334,280476,47948,907Aug 06 05:21 PM
Silva Paul MSVP & Corp ControllerAug 02Option Exercise91.051,289117,36317,376Aug 06 05:38 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Option Exercise91.051,796163,52640,909Aug 06 05:42 PM
Sachdev AmitEVP, CROAug 02Option Exercise91.052,155196,21348,817Aug 06 06:19 PM
Sachdev AmitEVP, CROAug 02Sale176.732,155380,85246,662Aug 06 06:19 PM
ALTSHULER DAVIDEVP, Global Research and CSOAug 02Sale174.591,796313,56439,113Aug 06 05:42 PM
Silva Paul MSVP & Corp ControllerAug 02Sale174.591,289225,04716,087Aug 06 05:38 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerAug 02Sale176.784,280756,61646,752Aug 06 05:21 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Option Exercise96.872,125205,84948,877Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 16Option Exercise96.871,719166,52048,381Jul 17 06:30 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Option Exercise131.8923,3753,082,92962,488Jul 18 05:32 PM
Silva Paul MSVP & Corp ControllerJul 16Option Exercise96.8786083,30816,947Jul 18 05:44 PM
Silva Paul MSVP & Corp ControllerJul 16Sale179.85860154,67116,087Jul 18 05:44 PM
ALTSHULER DAVIDEVP, Global Research and CSOJul 16Sale182.0023,3754,254,25039,113Jul 18 05:32 PM
Sachdev AmitEVP, CROJul 16Sale180.361,719310,04246,662Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 16Sale179.852,125382,18146,752Jul 17 06:23 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Option Exercise131.896,375840,79953,127Jul 17 06:23 PM
Sachdev AmitEVP, CROJul 13Option Exercise96.8712,0311,165,44358,693Jul 17 06:30 PM
Sachdev AmitEVP, CROJul 13Sale180.0012,0312,165,58046,662Jul 17 06:30 PM
Arbuckle Stuart AEVP\Chief Commercial OfficerJul 13Sale179.006,3751,141,12546,752Jul 17 06:23 PM